List of Excipients in Branded Drug TECFIDERA

Tecfidera Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Tecfidera is an oral delayed-release capsule containing dimethyl fumarate (DMF), a small-molecule treatment for relapsing forms of multiple sclerosis. Its excipient strategy is commercially important because the product must protect DMF from gastric exposure, control release into the intestine, support capsule manufacture, and manage gastrointestinal tolerability. The strongest opportunities are in generic differentiation, enteric-coating technology, excipient substitution, contract development and manufacturing, and next-generation fumarate formulations.

What excipients are used in Tecfidera capsules?

Tecfidera uses a delayed-release hard gelatin capsule with an enteric polymer coating. The formulation contains conventional solid-dose excipients rather than a novel drug-delivery platform.

Formulation component	Function
Dimethyl fumarate	Active pharmaceutical ingredient
Microcrystalline cellulose	Diluent and compression or encapsulation aid
Croscarmellose sodium	Disintegrant
Talc	Glidant, anti-tacking agent and coating aid
Colloidal silicon dioxide	Flow aid
Magnesium stearate	Lubricant
Methacrylic acid copolymer, Type C	Enteric coating polymer
Triethyl citrate	Plasticizer for the enteric coating
Gelatin	Capsule shell
Titanium dioxide	Capsule opacifier
FD&C Blue No. 2	Capsule colorant

The FDA prescribing information identifies Tecfidera as a 120 mg or 240 mg delayed-release capsule. The product is administered twice daily after initial dose escalation.[1]

The key formulation element is the enteric coating. DMF can cause gastrointestinal adverse events, including flushing, abdominal pain, diarrhea and nausea. Delayed release reduces exposure in the stomach and shifts dissolution toward the intestine. The excipient system therefore has both pharmaceutical performance and commercial value.

How does Tecfidera’s enteric formulation work?

Tecfidera’s coating uses a pH-dependent methacrylic acid copolymer. The polymer remains relatively intact in the acidic gastric environment and dissolves at a higher intestinal pH. Triethyl citrate improves film flexibility and reduces brittleness during coating, storage and transport.

The formulation must meet several performance requirements:

1. Maintain capsule integrity during handling.
2. Resist premature release in gastric fluid.
3. Release DMF consistently in intestinal conditions.
4. Avoid excessive coating weight that slows or destabilizes dissolution.
5. Limit batch-to-batch variability.
6. Protect the drug from moisture and thermal stress.

For a generic developer, matching the reference product requires more than reproducing the named excipients. The developer must demonstrate comparable dissolution behavior, manufacturing robustness and bioequivalence under the applicable FDA pathway.

What formulation patents protect Tecfidera?

Tecfidera’s principal historical protection came from patents covering fumaric acid ester treatment and delayed-release pharmaceutical formulations. The central U.S. patent dispute involved Biogen’s U.S. Patent No. 8,399,514, which covered methods of treating multiple sclerosis with specified dimethyl fumarate dosing.[2]

The core composition and method-of-use patent protection did not prevent generic entry after the 2020 loss-of-exclusivity period. Generic manufacturers obtained FDA approvals after Paragraph IV litigation and related patent challenges.

Protection category	Commercial relevance
DMF therapeutic use	Protects treatment of multiple sclerosis with defined dosing
Delayed-release dosage form	Supports intestinal delivery and GI tolerability
Enteric coating composition	May limit direct formulation copying if claim scope is specific
Manufacturing process	Can create process barriers even where composition claims expire
Labeling and method-of-use claims	May affect skinny-label generic strategies
Drug-device or capsule technology	Limited relevance for the current Tecfidera product

Patent protection should be assessed through the current FDA Orange Book, the USPTO Patent Center and individual litigation records. Orange Book listings can change as listed patents expire, are delisted or become commercially irrelevant.[3]

When did Tecfidera lose exclusivity?

Tecfidera lost meaningful U.S. market exclusivity in 2020 as generic DMF products entered after patent litigation. The product’s new chemical entity exclusivity period had already expired, and generic applicants challenged remaining patent barriers through Paragraph IV certifications.

The commercial consequence was a rapid shift from branded monopoly economics to a multi-source market. Biogen retained the Tecfidera brand, but generic DMF manufacturers gained access to the same 120 mg and 240 mg strengths.

Event	Approximate timing
FDA approval of Tecfidera	2013
Initial branded market exclusivity	Expired before generic launch
Generic patent challenges	Primarily during the late 2010s
First U.S. generic approvals	2020
Broad multi-source competition	2020 onward
Current market structure	Brand, authorized or traditional generics, and competing fumarates

Exact generic launch rights depend on the individual ANDA, litigation outcome, settlement terms and commercial decision of each applicant.

Which companies challenged Tecfidera patents?

Generic manufacturers that pursued U.S. DMF approvals included Mylan, Amneal, Zydus and other ANDA sponsors. The litigation centered on whether Biogen’s patent claims were valid and enforceable, including written-description and obviousness issues.

Tecfidera litigation created a high-value Paragraph IV opportunity because the product had substantial sales before generic entry. The dispute also demonstrated the commercial importance of method-of-use patents for products whose active ingredient had been known before the branded indication.

Generic applicants generally used one of three strategies:

• Challenge listed patents through Paragraph IV certifications.
• Wait for patent expiry or a favorable court outcome.
• Enter under a label that omits protected indications where a legally viable skinny-label pathway exists.

The resulting competitive market reduced the value of direct brand substitution but increased demand for efficient, reliable excipient and coating supply.

What excipient opportunities exist for Tecfidera generics?

1. Enteric-polymer substitution

The primary opportunity is development of alternative enteric systems using polymers such as:

• Methacrylic acid copolymers with different dissolution thresholds.
• Hypromellose phthalate.
• Hypromellose acetate succinate.
• Polyvinyl acetate phthalate.
• Ethylcellulose combined with pH-sensitive polymers.

A substitute polymer can reduce dependence on a single supplier, lower coating costs or improve dissolution control. The formulation must still demonstrate pharmaceutical equivalence and bioequivalence.

2. Lower-cost coating processes

Coating process optimization can improve generic margins. Important variables include:

• Polymer concentration.
• Plasticizer ratio.
• Talc loading.
• Spray rate.
• Inlet and product temperature.
• Pan speed.
• Coating weight gain.
• Drying endpoint.

A process that reduces coating weight while preserving gastric resistance can lower material consumption and manufacturing time. Continuous coating and improved atomization may further reduce batch variability.

3. GI-tolerability differentiation

The current Tecfidera formulation is associated with gastrointestinal adverse events. A developer could pursue a product with improved tolerability through:

• More precise intestinal release.
• Multiparticulate capsules.
• Reduced local DMF concentration.
• Alternative release thresholds.
• Modified-release bead systems.
• Combination dosing with food-compatible administration instructions.

Any clinically meaningful tolerability claim would require appropriate clinical evidence. A formulation change alone does not establish superior tolerability.

4. Moisture-control systems

DMF formulation stability can be affected by moisture, coating permeability and storage conditions. Commercial opportunities include:

• High-barrier blister packaging.
• Desiccant-containing bottles.
• Moisture-resistant capsule shells.
• Improved polymer film systems.
• Lower water-activity excipient grades.
• Packaging designed for pharmacy-level repackaging.

Packaging improvements can support longer shelf life, reduce complaints and improve distribution into humid markets.

5. Excipient supply and dual sourcing

The product uses established, widely available excipients. That limits premium pricing for commodity materials but creates recurring demand for qualified pharmaceutical grades.

The most commercially relevant suppliers are those able to provide:

• Consistent particle-size distributions.
• Low bioburden and controlled elemental impurities.
• Reliable compendial documentation.
• Regulatory support for DMF or ANDA submissions.
• Dual-region manufacturing capacity.
• Technical assistance for coating scale-up.

A supplier that can qualify both the enteric polymer and plasticizer system has greater strategic value than a commodity distributor supplying only talc or magnesium stearate.

What regulatory pathway applies to a Tecfidera formulation?

A conventional generic Tecfidera capsule is generally developed through an abbreviated new drug application under Section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must establish pharmaceutical equivalence and bioequivalence to the reference listed drug.[4]

A materially different formulation may require a 505(b)(2) application if the sponsor relies partly on FDA findings for DMF but introduces a new dosage form, delivery system, dosing schedule or clinical claim.

Product strategy	Likely regulatory pathway
Same strength and conventional delayed-release capsule	505(j) ANDA
Different excipients with equivalent performance	Usually 505(j), subject to FDA requirements
New multiparticulate release technology	May require 505(b)(2)
New dosing schedule	May require 505(b)(2) and clinical support
New indication	505(b)(2) or supplemental pathway, depending on product
Novel combination product	Potentially 505(b)(2) or full application

FDA review focuses on product sameness, dissolution, impurities, stability and bioequivalence. Excipients that alter release behavior can create regulatory risk even when each individual excipient is well established.

What is the Orange Book status of Tecfidera?

Tecfidera is listed in the FDA Orange Book as a prescription delayed-release oral capsule. The Orange Book identifies the reference listed drug, dosage forms and relevant patent or exclusivity information.[3]

The practical Orange Book issues are:

• Whether a listed patent remains unexpired.
• Whether a generic applicant must provide a Paragraph IV certification.
• Whether an indication can be carved out.
• Whether a patent is relevant to the proposed product.
• Whether the listed patent has survived litigation.
• Whether the commercial launch date is restricted by settlement.

Tecfidera has no biosimilar pathway because DMF is a synthetic small molecule, not a biologic. Biosimilar risk is therefore irrelevant. The relevant competitors are ANDA-approved generics, authorized generic products and branded fumarate therapies.

How does Tecfidera compare with Vumerity and other fumarates?

Vumerity contains diroximel fumarate and is designed to generate the same active metabolite, monomethyl fumarate, while seeking improved gastrointestinal tolerability relative to DMF. It is a branded, clinically differentiated competitor rather than a conventional generic substitute.[5]

Product	Active ingredient	Dosage form	Main commercial position
Tecfidera	Dimethyl fumarate	Delayed-release capsule	Original high-volume fumarate brand
Generic DMF	Dimethyl fumarate	Delayed-release capsule	Price-driven substitution
Vumerity	Diroximel fumarate	Delayed-release capsule	Branded alternative with tolerability positioning
Bafiertam	Monomethyl fumarate	Delayed-release capsule	Direct active-metabolite strategy
Aubagio	Teriflunomide	Oral tablet	Non-fumarate oral MS competitor
Gilenya	Fingolimod	Oral capsule/tablet	Alternative oral disease-modifying therapy

The strongest excipient opportunity is not necessarily a direct Tecfidera copy. A polymer or multiparticulate platform that improves GI tolerability across fumarate products could have greater licensing value.

What generic entry risks exist for Tecfidera?

Generic entry risk is high because multiple manufacturers have already entered or pursued approval, the active ingredient is a small molecule, and the product does not require a complex device or biologic manufacturing process.

Remaining commercial risks include:

• Price erosion from multiple ANDA holders.
• Supply interruptions involving enteric polymers.
• Dissolution failures after scale-up.
• Capsule-shell or colorant changes requiring regulatory review.
• Labeling differences that restrict substitution.
• Manufacturing deviations affecting coating uniformity.
• Patent disputes over new formulation or method-of-use claims.
• Pharmacy substitution pressure against the brand.

For excipient companies, the risk profile is different. Commodity pricing may compress margins, but regulatory qualification and switching costs can create customer retention once a material is embedded in an approved ANDA.

How strong is the Tecfidera excipient patent estate?

The excipient patent estate is narrower than the broader Tecfidera therapeutic patent estate. Conventional materials such as microcrystalline cellulose, croscarmellose sodium, talc, silica and magnesium stearate generally do not provide meaningful standalone exclusivity.

Potentially stronger protection can arise from:

• Specific polymer combinations.
• Defined coating weight ranges.
• Dissolution profiles.
• Multiparticulate structures.
• Moisture-control systems.
• Manufacturing parameters linked to product performance.
• Clinical tolerability claims tied to release behavior.

A new patent strategy should focus on measurable formulation attributes and manufacturing controls rather than generic claims covering known enteric excipients. Freedom-to-operate analysis must distinguish expired Tecfidera patents from later patents covering improved fumarate delivery systems.

What licensing opportunities exist around Tecfidera excipients?

The most viable licensing opportunities are platform-based rather than Tecfidera-specific.

Excipient and coating technology

A polymer supplier can license:

• Ready-to-use aqueous enteric dispersions.
• Low-temperature coating systems.
• High-barrier film technology.
• Taste-masking or GI-release platforms.
• Coating processes optimized for DMF.

Generic product development

A contract development organization can offer a complete package covering:

• Formulation screening.
• Coating optimization.
• Dissolution method development.
• Stability studies.
• Scale-up.
• ANDA support.
• Commercial manufacturing transfer.

International supply arrangements

Geographic coverage is commercially relevant. A supplier with facilities in North America, Europe and Asia can support multi-market registration and reduce dependence on a single manufacturing site. Excipients must meet the applicable pharmacopoeial and regulatory standards in each jurisdiction.

Key Takeaways

• Tecfidera uses a conventional delayed-release capsule with a pH-sensitive methacrylic acid copolymer coating.
• The enteric coating, not the commodity filler system, is the primary formulation value driver.
• Generic DMF competition began in the U.S. in 2020 after Paragraph IV patent challenges.
• Tecfidera has no biosimilar risk because DMF is a synthetic small molecule.
• Commercial opportunities include polymer substitution, coating-process optimization, moisture control and multiparticulate delivery.
• A 505(j) ANDA is the standard route for an equivalent delayed-release capsule; materially different delivery systems may require 505(b)(2).
• New intellectual-property value is more likely in release profiles, coating processes and tolerability-linked formulations than in conventional excipient selection.
• Vumerity and Bafiertam create competitive demand for improved fumarate tolerability and delivery platforms.

FAQs

Can a generic Tecfidera product use different excipients?

Yes. A generic applicant may use different inactive ingredients if the product meets FDA requirements for pharmaceutical equivalence, bioequivalence, stability, safety and performance.

Is the Tecfidera enteric coating proprietary?

The general use of methacrylic acid copolymers and triethyl citrate is established pharmaceutical practice. Exclusivity depends on the specific formulation claims, coating parameters and unexpired patents, not on the generic concept of enteric coating.

Can an excipient supplier patent a better Tecfidera formulation?

Yes. Patentable subject matter may include a novel polymer combination, defined dissolution profile, multiparticulate system or manufacturing process that provides an unexpected technical or clinical benefit.

Would a liquid DMF formulation compete directly with Tecfidera?

It would be a substantially different dosage form and would likely require a more complex regulatory and clinical strategy. Liquid DMF would also create stability, taste, dosing and GI-tolerability challenges.

Do Tecfidera generics create opportunities for specialty packaging suppliers?

Yes. Moisture-resistant blister systems, desiccant packaging and pharmacy-stable unit-dose formats can support generic manufacturers seeking longer shelf life, lower handling risk and differentiated distribution economics.

References

1. U.S. Food and Drug Administration. (2024). Tecfidera (dimethyl fumarate) delayed-release capsules: Prescribing information. https://www.accessdata.fda.gov
2. U.S. Patent No. 8,399,514. (2013). Methods of treating multiple sclerosis. United States Patent and Trademark Office. https://patents.google.com/patent/US8399514
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
4. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process. https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
5. U.S. Food and Drug Administration. (2019). Vumerity (diroximel fumarate) delayed-release capsules: Prescribing information. https://www.accessdata.fda.gov